title: PTH treatment in hypoparathyroidism.
abstract: Hypoparathyroidism (HypoPT) is one of the few major hormone deficiency diseases that are not usually treated with the missing hormone. Bovine parathyroid hormone (PTH) has been purified and used as experimental treatment, as long back as in 1928 by Fuller Albright. Treatment, however, was abolished mainly because of antibody formation and costs. The recent approval of fully humanized truncated parathyroid hormone (Teriparatide, PTH (1-34)) and intact parathyroid hormone (Preotact, PTH(1-84)) for treatment of osteoporosis, has made the PTH drugs more accessible and thereby made clinical trials with PTH treatment of HypoPT feasible. Resent clinical trials have shown that treatment with PTH (1-34) and PTH (1-84) can stabilize plasma calcium, normalize plasma phosphate and reduce urine excretion of calcium. Furthermore, it seems that some patients with hypoPT experience an improved quality of life when treated with PTH compared with conventional treatment with 1α-hydroxylated vitamin D metabolites and calcium supplements.
authors.affiliation: Department of Endocrinology and Internal Medicine, Aarhus University Hospital THG, Tage-Hansens Gade 2, DK-8000 Aarhus C, Denmark. tanja.sikjaer@gmail.com
authors.forename: Tanja
authors.initials: T
authors.lastname: Sikjaer
authors.forename: Lars
authors.initials: L
authors.lastname: Rejnmark
authors.forename: Leif
authors.initials: L
authors.lastname: Mosekilde
mesh_terms: D000818:Animals; D002118:Calcium / Q000008:administration & dosage / Q000097:blood*; D002417:Cattle; D006801:Humans; D007011:Hypoparathyroidism / Q000188:drug therapy* / Q000503:physiopathology; D010281:Parathyroid Hormone / Q000627:therapeutic use*; D010710:Phosphates / Q000097:blood; D011788:Quality of Life; D019379:Teriparatide / Q000627:therapeutic use; D014807:Vitamin D / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D010281:Parathyroid Hormone; D010710:Phosphates; D019379:Teriparatide; D014807:Vitamin D; D002118:Calcium